Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated Non-small Cell Lung Cancer (NSCLC)

NCT06018688 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.

NCT NCT06018688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06018688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 15, 2023
Completion date
September 1, 2026
Enrollment
44 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, non small cell lung cancer